Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast C

[News]

BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.

More... (http://www.news-medical.net/news/20100621/Independent-DMC-recommends-continuation-of-BioSantes-ongoing-LibiGel-CV-and-Breast-Cancer-Safety-Study.aspx)